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Volume 59, Number 6S Abstracts 33Sstudies, and clinical implantation of the graft. Banked hu-
man aortic smooth muscle cells were cultured in bioreac-
tors in vitro to produce vascular tissue grafts, and a
decellularization process was subsequently used to remove
immunogenic cellular antigens. Arteriovenous grafts were
implanted into nonhuman primates for up to 6 months
and were evaluated for patency, durability, cannulation,
rejection, and cellular repopulation. In addition, these
grafts were evaluated for long-term arterial reconstruction
in a canine model, using canine-derived grafts. In animal
studies, histologic analysis demonstrated evidence of host
vascular cell migration into grafts and endothelialization.
Little intimal hyperplasia was observed in animal studies.
These preclinical studies supported initiation of clinical
trials.
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Objectives: Optimal initial treatment for patients with
acute limb ischemia (ALI) remains undeﬁned. Although
clinical outcome data are inconsistent, catheter-directed
thrombolysis (CDT) with tissue plasminogen activator is
increasingly used. Patient-level analysis combining clinical
and economic data in a real-life setting is lacking. This
study compares clinical outcomes and cost effectivenessTable. Clinical and economic outcomes
Variable CDT (n ¼ 68) CDT + A (n ¼ 16) Open
AFS (%/N) 94/64 87/14
Readmissions (%/N) 16/11 31/5
Mortality (%/N) 0 6/1
Major bleed (%/N) 3/2 0
Reinterventions (%/N) 62/42 33/5
Initial hosp costs, $
Mean 31,804 27,779
SE 2436 5035
Readmission cost ($)
Mean 20,441 26,844
SE 4684 7306
Total cost
Mean 34,840 37,002
SE 2725 5628of initial treatment strategies for non-embolic ALI using
real-life patient-level data.
Methods: Medical records and hospital cost data were
analyzed for non-embolic ALI patients treated in four hos-
pitals over 3 years. A cost-effectiveness analysis was per-
formed using a decision tree analytical model. All costs
were valued based on cost-to-charge ratios.
Results: In 205 patients, initial treatments were CDT
alone (68) or with angioplasty (16), open surgery (60),
endovascular (33), and hybrid (28). Clinical and economic
outcomes are summarized in the Table. Although clinical
outcomes did not differ signiﬁcantly between groups, rein-
tervention rates during hospital stay, readmission rates, and
costs were highest in the CDT group. More than one re-
intervention was needed in 16% of patients in the CDT
group.
Conclusions: In this real-life study, initial treatment
of non-embolic limb ALI with currently available CDT
options was associated with greater healthcare resource
consumption and cost compared to other initial treatment
options.
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Objectives: To evaluate our extensive experience in
the treatment of patients with neurogenic thoracic outlet
syndrome (NTOS) who underwent ﬁrst rib resection and
scalenectomy (FRRS) over a decade.
Methods: Patients treated with FRRS for NTOS from
2003 to 2013 were retrospectively reviewed using a pro-
spectively maintained database.
Results: Over the 10 years, 286 patients underwent
308 FRRS. During the ﬁrst 5-year period, 127 FRRS
were performed (96 female, 31 male), with an average
age of 36.9 years. During the second 5-year period, 181
FRRS were performed (143 female, 38 male), with an
average age of 33 years. Twenty-four children (age #18
years) underwent FRRS; nine during the ﬁrst 5 years andSurg (n ¼ 60) Endovasc (n ¼ 33) Hybrid (n ¼ 28) P
95/57 100/33 100/28 NS
7/4 6/2 3/1 <.05
1/1 0 0 NS
1/1 0 0 NS
7/4 12/4 18/5 <.00001
.01
16,636 20,751 21,134
2595 3494 3850
.05
7434 24,409 4156
9847 11,235 18,117
.0001
17,758 21,916 21,220
2921 3911 4309
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34S Abstracts June Supplement 201415 during the second 5 years. When comparing the second
5-year period with the ﬁrst 5-year period, patients were
younger (P ¼ .066), reported a signiﬁcantly shorter length
of preoperative symptoms (35.4 vs 52.1 months, P < .01),
prior narcotic use decreased from 31.5% to 23.8% (P <
.05), and a history of prior surgical intervention on the ipsi-
lateral side (head, neck, shoulder) increased from 30.1% to
51.9% (P < .01). Use of lidocaine blocks as a diagnostic
tool (57% to 35.4%, P ¼ .06) and Botox blocks as a ther-
apeutic tool (29.1% to 12.7%, P < .01) decreased in the
second 5 years with similar positive results. Improved or
fully resolved symptoms after FRRS increased from 89%
in the ﬁrst 5 years to 92.8% in the second 5 years. Average
length of follow-up over the 10-year period was 13.4
months.
Conclusions: (1) Excellent results were seen in this
largest surgical series reported for NTOS. (2) Younger pa-
tients with shorter duration of symptoms with less
narcotic use led to even better FRRS results in the second
5 years of surgical intervention. (3) An established
vascular practice for referrals for NTOS resulted in an
increased number of appropriate patients for surgical
intervention, requiring less lidocaine and/or botox injec-
tions preoperatively.
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Objectives: Medical management (MM) with anti-
platelet and statin therapy is recommended for most pa-
tients undergoing vascular surgery. We tested the
association of Vascular Quality Initiative (VQI) participa-
tion and perioperative MM use over time and the effect
of optimal MM on patient survival.
Methods: We studied VQI patients treated with MM
preoperatively and at discharge from 2005 to 2013,
including all elective carotid endarterectomy (CEA)/ca-
rotid artery stenting (CAS; n ¼ 19,428), supra/infraingui-
nal bypass (n ¼ 8,462), peripheral vascular interventions (n
¼ 15,525), and open/endovascular abdominal aortic aneu-
rysm repair (n ¼ 9,530). We examined trends of MM useover time, as well as the effect of duration of VQI partici-
pation on MM use. Multivariable analyses were performed
to identify factors associated with MM use and 2-year
survival.
